Emerens Wensink, MD, Ph.D. Candidate from University Medical Center Utrecht, Utrecht University discusses Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.
Link to Abstract –
https://pubmed.ncbi.nlm.nih.gov/33046804/
Instract
Context:Â
The analysis of single-arm immunotherapy research is complicated by negligible evidence on survival during systemic non-immunotherapy. A broad, systematic cohort of dMMR mCRC patients treated with or without systemic non-immunotherapy is provided with survival results.
Methods:Â
Overall survival was analyzed based on mCRC (OS) diagnosis, first-line (OS1), and second-line (OS2) systemic treatment initiation. Prognostic variables were investigated by Cox regression analysis. Compared with OS 2746, MMR proficient mCRC patients have been reported.
Results:Â
Median OS in untreated patients was 16.0 months (13.8-19.6) with antitumor treatment and 2.5 months (1.8-3.5). OS1 in treated dMMR patients was 12.8 months (10.7-15.2) and OS2 was 6.2 months (5.4-8.9). Treated patients with dMMR had a 7.6-month shorter median OS than patients with pMMR.
Conclusion:Â
There is a lack of a control arm with standard systemic treatment available from immunotherapy trial results. Given the bad outcome relative to immunotherapy outcomes, our results clearly indicate that immunotherapy in dMMR mCRC patients has a survival advantage.